cagrisema glp 1 Did Not Meet Primary End Point of Noninferiority to Tirzepatide cagrisema glp 1 first glp

In rats with CLP-induced SLI, deferoxamine treatment significantly reduced ACSL4 protein levels, accompanied by decreased lipid peroxidation, ultimately improving the SLI (Zhang et al., 2025b)

10.1210/en.2003-2350 Endocrinology 71 GuertinD

A recent meta-analysis, which analysed data from the EMPA-REG OUTCOME trial and the VERTS CV study, suggested that the administration of empagliflozin/ertugliflozin significantly reduced the risk of developing new-onset OSA by 47% ( p = 0.003) [103]

A careful reading of the literature therefore requires separating molecular identity, in vitro mechanism, preclinical animal-model outcomes, and human relevance as distinct levels of evidence